Novo Holdings A/S Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001388325

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 26 positions · Total reported value $1.49B · Top-10 concentration 76.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.7% · 2 new · 8 cut · 1 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.9% · vs SPY -15.1% · Prev Value $1.72B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.6% · vs SPY -2.8% · Latest Value $1.49B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Novo Holdings A/S disclosed 26 equity positions with a combined reported value of $1.49B. The filing implies a focused portfolio: its ten largest positions account for 76.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were EWTX ($217.21M), ASML ($172.01M), BN ($162.80M). By sector, the heaviest allocations are Health Care 67.0%, Technology 17.7%. Versus the prior quarter, allocation shifted toward Technology (+2.8pp), Real Estate (+2.2pp) and away from Health Care (-2.3pp), Other (-2.9pp).

Versus the prior quarter, Novo Holdings A/S opened 2 new positions, trimmed 8 and fully exited 1, a turnover rate of 40.7% of positions. The portfolio's overlap with the prior quarter was 89% of names.

The largest new positions opened in Q3 2026 were SRRK ($22.23M), CTNM ($9.45M).

Of the 1 positions fully exited versus the prior quarter, the largest were CRNX ($49.39M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SRRK SCHOLAR ROCK HLDG CORP · $22.23M
  • CTNM CONTINEUM THERAPEUTICS INC · $9.45M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $49.39M

Insider Transactions (Form 4)

Latest Novo Holdings A/S buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-04 Conversion Hemab Therapeutics Holdings, Inc. 4,180,550 — SEC filing
2026-05-01 Buy Avalyn Pharma Inc. 555,555 $18.00 SEC filing
2026-05-01 Conversion Avalyn Pharma Inc. 3,327,734 — SEC filing

All insider transactions →

Fund Profile

Novo Holdings A/S files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 26 positions worth $1.49B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 26 positions · $1.49B reported value (Q3 2026)
  • Top 10 holdings = 76.1% of reported value
  • Largest position: EWTX (EDGEWISE THERAPEUTICS INC) at 14.6%
  • Average position size: $57.30M

Sector Tilt

  • Health Care 67.0%
  • Information Technology 17.7%
  • Real Estate 10.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 6 added, 8 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to Health Care (up 3.5% YoY) and Real Estate (up 2.25% YoY), while reducing Technology (down 0.42% YoY), suggesting a bullish stance on biotech/healthcare and real estate, with modest tech profit-taking. 2. Key moves: - Added: BN (Brookfield Corp, +27.7% shares), VRDN (Viridian Therapeutics, +128.3% shares). - Reduced: AVLN (Avalyn Pharmaceuticals, -11.2% shares), FDMT (4D Molecular Therapeutics, -7.7% shares). 3. Portfolio structure: Active, concentrated (top 10 = 75.99%), overweight Health Care (60.17%) vs. Technology (17.61%), with high risk (small/mid-cap biotech focus). 4. Per-holding one-liner: - EWTX: Edgewise Therapeutics (biotech, unverified). - ASML: ASML Holding (semiconductor equipment). - BN: Brookfield Corp (real estate/infrastructure). - COAG: Hemab Therapeutics (biotech, unverified). - AVLN: Avalyn Pharmaceuticals (biotech, unverified). - MIRM: Mirum Pharmaceuticals (biotech, unverified). - CRM: Salesforce (cloud software). - VRDN: Viridian Therapeutics (thyroid disease biotech, unverified). - ELVN: Enliven Therapeutics (biotech, unverified). - FDMT: 4D Molecular Therapeutics (gene therapy, unverified). 5. Style summary: Biotech/real estate overweight with selective tech additions, active management favoring high-growth therapeutics.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:27

Sector Allocation

Health Care 67.0%
Technology 17.7%
Real Estate 10.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.35M $217.21M 14.58%
14.58%
Hold
2 94.95K $172.01M 11.55%
11.55%
Hold
3 4.47M $162.80M 10.93%
10.93%
Add
4 4.18M $128.93M 8.65%
8.65%
Hold
5 3.45M $98.27M 6.60%
6.60%
Reduce
6 1.12M $96.17M 6.46%
6.46%
Hold
7 393.19K $90.26M 6.06%
6.06%
Hold
8 4.87M $78.92M 5.30%
5.30%
Add
9 1.00M $45.84M 3.08%
3.08%
Hold
10 3.00M $42.93M 2.88%
2.88%
Reduce
11 710.00K $40.40M 2.71%
2.71%
Reduce
12 797.00K $36.51M 2.45%
2.45%
Hold
13 1.18M $35.58M 2.39%
2.39%
Reduce
14 284.43K $32.46M 2.18%
2.18%
Add
15 1.02M $32.34M 2.17%
2.17%
Reduce
16 950.00K $30.79M 2.07%
2.07%
Reduce
17 257.33K $27.67M 1.86%
1.86%
Hold
18 652.11K $24.25M 1.63%
1.63%
Add
19 460.00K $22.23M 1.49%
1.49%
New
20 1.38M $22.17M 1.49%
1.49%
Add
21 2.09M $21.26M 1.43%
1.43%
Reduce
22 704.01K $9.45M 0.63%
0.63%
New
23 1.25M $9.24M 0.62%
0.62%
Add
24 2.25M $9.22M 0.62%
0.62%
Hold
25 110.39K $1.88M 0.13%
0.13%
Reduce
26 158.15K $903.02K 0.06%
0.06%
Hold

FAQ

What did Novo Holdings A/S buy in 2026-Q3?

In its 2026-Q3 13F filing, Novo Holdings A/S reported 26 equity positions worth $1.49B in aggregate; its largest disclosed positions were EWTX ($217.21M), ASML ($172.01M), BN ($162.80M).

How large is Novo Holdings A/S's portfolio?

Novo Holdings A/S reported $1.49B of long equity holdings across 26 positions as of 2026-Q3. Top-10 holdings account for 76.1% of reported value.

What is Novo Holdings A/S's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/novo-holdings-a-s/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →